Press release
Adult-onset Still Disease (AOSD) market growing at a CAGR of around 7.7%
Adult-onset Still Disease (AOSD) market
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71305
Key Market Drivers
• Increasing awareness and improved identification of AOSD cases.
• Growing use of IL-1 and IL-6 inhibitors as first-line biologic therapies.
• Advances in ferritin and inflammation-marker testing supporting earlier diagnosis.
• Expansion of rheumatology clinics and specialist centers.
Challenges
• High cost of biologic drugs.
• Misdiagnosis due to overlap with other inflammatory diseases.
• Small patient pool limiting large-scale clinical data.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71305/adult-onset-still-disease-market
Market Segmentation
By Treatment
• Biologics (main revenue generator)
• Non-biologics (corticosteroids, DMARDs)
• Symptomatic therapies
By Diagnosis
• Laboratory tests
• Imaging techniques
• Differential diagnostic evaluations
By End User
• Hospitals
• Specialty rheumatology clinics
• Homecare (for stable patients)
By Distribution Channel
• Retail pharmacies
• Online pharmacies
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71305
Regional Snapshot
• North America leads due to high biologic usage and strong reimbursement.
• Europe shows steady adoption supported by specialty care centers.
• Asia-Pacific is the fastest-growing region due to rising disease recognition and expanding rheumatology infrastructure.
Key Companies
AbbVie, Roche, Novartis, Sanofi, Amgen, Pfizer, GSK, Biogen, UCB, Takeda, Johnson & Johnson.
Future Outlook
The market will continue expanding due to increased biologic adoption, better diagnostic precision, and growing access to specialist care. Personalized medicine and targeted cytokine therapies are expected to define the next decade of AOSD management.
This report is also available in the following languages : Japanese (成人発症スティル疾患市場), Korean (성인 발병 스틸병 시장), Chinese (成人斯蒂尔病市场), French (Marché de la maladie de Still de l'adulte), German (Markt für Still-Krankheit im Erwachsenenalter), and Italian (Mercato della malattia di Still ad esordio nell'adulto), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71305
Our More Reports:
Oropharyngeal Cancer Market
https://exactitudeconsultancy.com/reports/71260/oropharyngeal-cancer-market
Pancreatic Adenocarcinoma Market
https://exactitudeconsultancy.com/reports/71262/pancreatic-adenocarcinoma-market
Neurofibrosarcoma Market
https://exactitudeconsultancy.com/reports/71264/neurofibrosarcoma-market
Oncolytic Adenovirus Market
https://exactitudeconsultancy.com/reports/71266/oncolytic-adenovirus-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Adult-onset Still Disease (AOSD) market growing at a CAGR of around 7.7% here
News-ID: 4310931 • Views: …
More Releases from Exactitude Consultancy
Medullary Thyroid Cancer (MTC) Market is projected to reach USD 1.19 billion by …
The global Medullary Thyroid Cancer (MTC) Market was valued at USD 672 million in 2024 and is projected to reach USD 1.19 billion by 2034, growing at a CAGR of 5.8% from 2025 to 2034. Market growth is driven by increasing adoption of targeted therapies, improved genetic testing for RET mutations, rising incidence of thyroid cancers globally, and advancements in minimally invasive diagnostic and surgical techniques.
Download Full PDF Sample Copy…
Disseminated Intravascular Coagulation (DIC) Market was valued at USD 1.42 billi …
The Disseminated Intravascular Coagulation (DIC) Market is expanding as the global incidence of sepsis, trauma cases, obstetric complications, and malignancy-related coagulation disorders continues to rise. DIC is a serious, life-threatening hematological condition characterized by systemic activation of the coagulation cascade, leading to organ failure, hemorrhage, and microvascular thrombosis.
Demand for rapid diagnostics, advanced coagulation testing, and critical-care therapies has increased significantly in recent years.
The global DIC market was valued at USD…
Malignant Glioma Market is projected to reach USD 8.03 billion by 2034
The global Malignant Glioma Market was valued at USD 4.62 billion in 2024 and is projected to reach USD 8.03 billion by 2034, growing at a CAGR of 5.7% from 2025 to 2034. Market growth is fueled by increasing incidence of high-grade gliomas, rising adoption of targeted and immunotherapy approaches, continued innovation in brain tumor imaging and surgical technologies, and growing investment in precision oncology for central nervous system (CNS)…
Chemotherapy-Induced Febrile Neutropenia Market valued at USD 2.95 billion in 20 …
The Chemotherapy-Induced Febrile Neutropenia (CIFN) Market is expanding steadily due to the rising global cancer burden, increasing use of myelosuppressive chemotherapies, and growing demand for prophylactic and therapeutic neutropenia management. Febrile neutropenia is a common and potentially life-threatening complication in cancer patients, requiring rapid intervention and hospitalization. This market is driven by the rising adoption of granulocyte colony-stimulating factors (G-CSFs), improved oncology care infrastructure, and enhanced supportive-care protocols worldwide.
The global…
More Releases for AOSD
Still's Disease Treatment Market Poised for Significant Growth: Know Market Driv …
The Still's disease treatment market is poised for significant growth driven by increasing disease awareness, improved diagnostic capabilities, and the emergence of novel therapeutic options. This growth is fueled by the introduction of innovative biological therapies by key players including AB2 Bio Ltd, F.Hoffmann-La Roche Ltd, Novartis AG, Swedish Orphan Biovitrum AB, Jubilant Life Sciences Ltd, Hikma Pharmaceuticals PLC, Teva Pharmaceutical Industries Ltd, and Horizon Therapeutics, among others, which are…
Adult-onset Still Disease (AOSD) Market Projected to Grow by 2034 | Cerecor, Roc …
The growth of the Adult-onset Still Disease market is fueled by factors such as rising disease prevalence, increased investment in research and development, and the introduction of innovative therapies during the forecast period from 2020 to 2034.
The market report provides detailed insights into AOSD, including market size and share, epidemiology, emerging treatment options, key drivers and challenges, ongoing clinical trials, strategic collaborations, and therapy adoption by leading companies actively contributing…
Adult-Onset Still's Disease Market to Hit USD 2.5 Billion by 2034
Adult-Onset Still's Disease (AOSD) is a rare systemic autoinflammatory disorder characterized by spiking fevers, arthritis, rash, and elevated inflammatory markers. While its exact cause remains unknown, AOSD is thought to result from dysregulated immune responses involving interleukin (IL)-1, IL-6, and other inflammatory pathways.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71305
Historically, management relied on NSAIDs, corticosteroids, and immunosuppressants, but the past decade has seen major advances with biologic therapies…
Adult-Onset Still Disease Pipeline Insight 2025: IL-1/IL-6 Blockade, JAK Inhibit …
DelveInsight's "Adult-Onset Still Disease - Pipeline Insight, 2025" provides a detailed overview of the evolving therapeutic landscape for this rare systemic autoinflammatory disorder. Traditionally reliant on corticosteroids and conventional DMARDs, Adult-Onset Still Disease (AOSD) has long posed clinical challenges due to its relapsing course, systemic inflammation, and risk of complications such as macrophage activation syndrome.
The 2025 pipeline highlights the growing dominance of targeted biologics, particularly IL-1 and IL-6 inhibitors, which…
Still's Disease Treatment Market Poised for Significant Growth, Driven by Therap …
The Still's disease treatment market is poised for significant growth driven by increasing disease awareness, improved diagnostic capabilities, and the emergence of novel therapeutic options. This growth is fueled by the introduction of innovative biological therapies by key players, including AB2 Bio, Roche, Novartis, Swedish Orphan Biovitrum, Jubilant Life Sciences, Hikma, Teva, and Horizon, among others, which are addressing significant unmet needs in this rare inflammatory condition.
DelveInsight's "Still's Disease -…
Adult-Onset Still Disease Treatment Market Size in 7MM is expected to grow at a …
DelveInsight's "Adult-onset Still's Disease Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of AOSD, historical and forecasted epidemiology, as well as the AOSD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Unlock key insights into the Adult-onset Still Disease Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Adult-onset Still…
